Piper Sandler raised the firm’s price target on Prothena (PRTA) to $36 from $15 and keeps an Overweight rating on the shares. The firm recognizes the value of its partnered pipeline with lucrative potential across net sales royalties and milestone payments. Piper remains bullish on Prothena and believes that there is substantial upside opportunity heading into a catalyst-rich next 12 months-plus.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: